Myocardial fibrosis in stroke survivors

Wong, K.; Sze, S.; Wong, S.; McSwiggan, S.; Allgar, V.; MacWalter, R.; Struthers, A. D.

Abstract

Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death, ventricular tachyarrhythmia and heart failure. Procollagen carboxyl-terminal telopeptide (PICP) was found to be a marker of MF. The relationship between PICP and cardiac abnormalities in stroke survivors is unknown. We recently showed that MF in stroke survivors can be treated by spironolactone and amiloride in a randomised placebo-controlled cross-over study with reduction in PICP levels and QTc [1].

Citation

Wong, K., Sze, S., Wong, S., McSwiggan, S., Allgar, V., MacWalter, R., & Struthers, A. D. (2015). Myocardial fibrosis in stroke survivors. International journal of cardiology, 187(1), 138-140. https://doi.org/10.1016/j.ijcard.2015.03.212

• Journal Article Type: Article
• Acceptance Date: Mar 17, 2015
• Online Publication Date: Mar 19, 2015
• Publication Date: May 6, 2015
• Deposit Date: Apr 8, 2015
• Publicly Available Date: Apr 8, 2015
• Journal: International journal of cardiology
• Print ISSN: 0167-5273
• Electronic ISSN: 1874-1754
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 187
• Issue: 1
• Pages: 138-140
• DOI: https://doi.org/10.1016/j.ijcard.2015.03.212
• Keywords: Myocardial fibrosis, PICP, Stroke survivors
• Public URL: https://hull-repository.worktribe.com/output/372133
• Publisher URL: http://www.sciencedirect.com/science/article/pii/S0167527315004519
• Additional Information: Author's accepted manuscript of article which has been published in International journal of cardiology, 2015, v.187.